boehringer

Boehringer provides update on iclepertin Phase III program in schizophreniaBoehringer provides update on iclepertin Phase III program in schizophrenia

Boehringer provides update on iclepertin Phase III program in schizophrenia

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia,…

2 months ago
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogsBoehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

3 months ago
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogsBoehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

3 months ago
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogsBoehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

3 months ago
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogsBoehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

3 months ago
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogsBoehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

3 months ago
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogsBoehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

3 months ago
Boehringer Ingelheim Commits to Veeva Vault CRMBoehringer Ingelheim Commits to Veeva Vault CRM

Boehringer Ingelheim Commits to Veeva Vault CRM

Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches…

4 months ago
Boehringer Ingelheim Commits to Veeva Vault CRMBoehringer Ingelheim Commits to Veeva Vault CRM

Boehringer Ingelheim Commits to Veeva Vault CRM

Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches…

4 months ago